Acetylcholinesterase: Molecular modeling with the whole toolkit

Current Topics in Medicinal Chemistry

Volumn 6, Issue 1, 2006, Pages 57-73

  Lushington, Gerald H ^a   Guo, Jian Xin ^a   Hurley, Margaret M ^b  

^a UNIVERSITY OF KANSAS   (United States)

^b U S ARMY RESEARCH LABORATORY   (United States)

Author keywords

Acetylcholinesterase; Alzheimer's disease; COMBINE; Molecular docking; Molecular dynamics; Organophosphorus nerve agents; QSAR; Quantum chemistry

Indexed keywords

ACETYLCHOLINESTERASE; ACRIDINE DERIVATIVE; ALKALOID DERIVATIVE; BENZISOXAZOLE DERIVATIVE; BENZYL DERIVATIVE; BIPYRIDINE DERIVATIVE; CARBAMIC ACID DERIVATIVE; CHOLINESTERASE INHIBITOR; COUMARIN DERIVATIVE; DIAZEPINE DERIVATIVE; DONEPEZIL; EDROPHONIUM; FASCICULIN; HALOKETONE; HUPERZINE A; OPIATE DERIVATIVE; ORGANOPHOSPHORUS COMPOUND; OXAZOLE DERIVATIVE; PHENOTHIAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; PROPIDIUM IODIDE; PYRIDINIUM DERIVATIVE; QUINAZOLINE DERIVATIVE; QUINOLONE DERIVATIVE; SOMAN; STEROID; TACRINE DERIVATIVE; TRYPTAMINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELNACRINE;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; BINDING SITE; COMPARATIVE MOLECULAR FIELD ANALYSIS; COMPUTER MODEL; COVALENT BOND; DRUG DESIGN; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INHIBITION; ENZYME KINETICS; ENZYME STRUCTURE; HUMAN; MOLECULAR DYNAMICS; MOLECULAR MODEL; MONTE CARLO METHOD; MYASTHENIA GRAVIS; NONHUMAN; PARKINSON DISEASE; PHARMACOPHORE; PROTEIN FUNCTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; QUANTUM MECHANICS; REVIEW; SEQUENCE HOMOLOGY; CHEMICAL MODEL; CHEMICAL STRUCTURE; CHEMISTRY; METABOLISM;

ACETYLCHOLINESTERASE; CHOLINESTERASE INHIBITORS; HUMANS; MODELS, CHEMICAL; MODELS, MOLECULAR;

EID: 33644850379     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802606775193293     Document Type: Review

References (107)

1. Quinn, D. M. Acetylcholinesterase - Enzyme Structure, Reaction Dynamics, and virtual transition-states. Chem. Rev. 1987, 87, 955-979.
2. Gentner, D. R., Rosenberg, R. N. Choline Acetyltransferase and acetylcholinesterase. Their role in the cause of myasthenia gravis. Arch. Neurol. 1972, 27, 21-25.
3. Perry, E. K., Perry, R. H., Blessed, G., Tomlinson, B. E. Changes in brain cholinesterase in senile dementia of Alzheimer type. Neuropathol. Applied Neurobiol. 1978, 4, 273-277.
4. Weinstock, M., Razin, M., chorev, M., Tashma, Z. Pharmacological activity of novel anticholinesterase agents of potential use in the treatment of Alzheimer disease. Adv. Behav. Biol. 1986, 29, 539-549.
5. Perry, E. K. The cholinergic system in old age and Alzheimer's disease. Age Ageing 1980, 9, 1-8.
6. Farlow, M. R.; Lilly, M. L. Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years. BMC Geriatr. 2005, 5, 3.
7. Windisch, M. Approach towards an integrative drug treatment of Alzheimer's disease. J. Neural. Transm. Suppl. 2000, 59, 301-313.
8. Sirvio, J.; Rinne, J. O.; Valjakka, A.; Rinne, U. K.; Riekkinen, P. J. et al. Different forms of brain acetylcholinesterase and muscarinic binding in Parkinson's disease. J. Neurol. Sci. 1989, 90, 23-32.
9. Stephenson, J. Exposure to home pesticides linked to Parkinson diseae. JAMA 2000, 283, 3055-3056.
10. Dvir, H.; Jiang, H. L.; Wong, D. M.; Harel, M.; Chetrit, M. et al. X-ray structures of Torpedo californica acetylcholinesterase complexed with (+)-huperzine A and (-)-huperzine B: structural evidence for an active site arrangement. Biochemistry 2002, 41, 10810-10818.
11. Bourne, Y.; Taylor, P.; Bougis, P. E.; Marchot, P. Crystal structure of mouse acetylcholinesterase. A peripheral site-occluding loop in a tetrameric assembly. J. Biol. Chem. 1999, 274, 2963-2970.
12. Kryger, G.; Harel, M.; Giles, K.; Toker, L.; Velan, B. et al. Structures of recombinant native and E202Q mutant human acetylcholinesterase complexed with the snake-venom toxin fasciculin-II. Acta Crystallogr. D Biol. Crystallogr. 2000, 56 (Pt 11), 1385-1394.
13. Orengo, C. A.; Michie, A. D.; Jones, S.; Jones, D. T.; Swindells, M. B. et al. CATH - a hierarchic classification of protein domain structures. Structure 1997, 5, 1093-1108.
14. Flores-Flores, C.; Martinez-Martinez, A.; Munoz-Delgado, E.; Vidal, C. J. Conversion of acetylcholinesterase hydrophilic tetramers into amphiphilic dimers and monomers. Biochem. Biophys. Res. Commun. 1996, 219, 53-58.
15. Vellom, D. C.; Radic, Z.; Li, Y.; Pickering, N. A.; Camp, S. et al. Amino acid residues controlling acetylcholinesterase and butyrylcholinesterase specificity. Biochemistry 1993, 32, 12-17.
16. Ariel, N., Barak, D., Velan, B., Shafferman, A. A. Molecular dynamics simulation of the Cys69-Cys96 surface loop in human acetylcholinesterase. Relevance to the conformational mobility of the 'anionic' subsite Trp86. Medical Defense Bioscience Review, Proceedings: Baltimore, 1996; pp 97-103.
17. Gilson, M. K.; Straatsma, T. P.; McCammon, J. A.; Ripoll, D. R.; Faerman, C. H. et al. Open "back door" in a molecular dynamics simulation of acetylcholinesterase. Science 1994, 263, 1276-1278.
18. Kronman, C.; Ordentlich, A.; Barak, D.; Velan, B.; Shafferman, A. The "back door" hypothesis for product clearance in acetylcholinesterase challenged by site-directed mutagenesis. J. Biol. Chem. 1994, 269, 27819-27822.
19. Bartolucci, C.; Perola, E.; Cellai, L.; Brufani, M.; Lamba, D. "Back door" opening implied by the crystal structure of a carbamoylated acetylcholinesterase. Biochemistry 1999, 38, 5714-5719.
20. Malany, S.; Baker, N.; Verweyst, M.; Medhekar, R.; Quinn, D. M. et al. Theoretical and experimental investigations of electrostatic effects on acetylcholinesterase catalysis and inhibition. Chem. Biol. Interact. 1999, 119-120, 99-110.
21. Sussman, J. L.; Harel, M.; Frolow, F.; Oefner, C.; Goldman, A. et al. Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein. Science 1991, 253, 872-879.
22. Ripoll, D. R.; Faerman, C. H.; Axelsen, P. H.; Silman, I.; Sussman, J. L. An electrostatic mechanism for substrate guidance down the aromatic gorge of acetylcholinesterase. Proc. Natl. Acad. Sci. USA 1993, 90, 5128-5132.
23. Felder, C. E.; Botti, S. A.; Lifson, S.; Silman, I.; Sussman, J. L. External and internal electrostatic potentials of cholinesterase models. J. Mol. Graph. Model. 1997, 15, 318-327, 335-337.
24. Botti, S. A.; Felder, C. E.; Lifson, S.; Sussman, J. L.; Silman, I. I. A modular treatment of molecular traffic through the active site of cholinesterase. Biophys. J. 1999, 77, 2430-2450.
25. Cousin, X., Hotelier, T., Chatonnet, A. The ESTHER Database. http://bioweb.ensam.inra.fr/ESTHER/general?what=sitemap.
26. Ashani, Y.; Radic, Z.; Tsigelny, I.; Vellom, D. C.; Pickering, N. A. et al. Amino acid residues controlling reactivation of organophosphonyl conjugates of acetylcholinesterase by mono- and bisquaternary oximes. J. Biol. Chem. 1995, 270, 6370-6380.
27. Shen, T.; Tai, K.; Henchman, R. H.; McCammon, J. A. Molecular dynamics of acetylcholinesterase. Acc. Chem. Res. 2002, 35, 332-340.
28. Axelsen, P. H.; Harel, M.; Silman, I.; Sussman, J. L. Structure and dynamics of the active site gorge of acetylcholinesterase: synergistic use of molecular dynamics simulation and X-ray crystallography. Protein Sci. 1994, 3, 188-197.
29. Kovach, I. M.; Qian, N.; Bencsura, A. Efficient product clearance through exit channels in substrate hydrolysis by acetylcholinesterase. FEBS Lett. 1994, 349, 60-64.
30. Tara, S.; Straatsma, T. P.; McCammon, J. A. Mouse acetylcholinesterase unliganded and in complex with huperzine A: a comparison of molecular dynamics simulations. Biopolymers 1999, 50, 35-43.
31. Shen, T. Y.; Tai, K.; McCammon, J. A. Statistical analysis of the fractal gating motions of the enzyme acetylcholinesterase. Phys. Rev. E Stat. Nonlin. Soft Matter Phys. 2001, 63, 041902.
32. Tai, K.; Shen, T.; Borjesson, U.; Philippopoulos, M.; McCammon, J. A. Analysis of a 10-ns molecular dynamics simulation of mouse acetylcholinesterase. Biophys. J. 2001, 81, 715-724.
33. Van Belle, D.; De Maria, L.; Iurcu, G.; Wodak, S. J. Pathways of ligand clearance in acetylcholinesterase by multiple copy sampling. J. Mol. Biol. 2000, 298, 705-726.
34. Tai, K.; Shen, T.; Henchman, R. H.; Bourne, Y.; Marchot, P. et al. Mechanism of acetylcholinesterase inhibition by fasciculin: a 5-ns molecular dynamics simulation. J. Am. Chem. Soc. 2002, 124, 6153-6161.
35. Bourne, Y.; Taylor, P.; Marchot, P. Acetylcholinesterase inhibition by fasciculin: crystal structure of the complex. Cell 1995, 83, 503-512.
36. Radic, Z.; Quinn, D. M.; Vellom, D. C.; Camp, S.; Taylor, P. Allosteric control of acetylcholinesterase catalysis by fasciculin. J. Biol. Chem. 1995, 270, 20391-20399.
37. Faerman, C.; Ripoll, D.; Bon, S.; Le Feuvre, Y.; Morel, N. et al. Site-directed mutants designed to test back-door hypotheses of acetylcholinesterase function. FEBS Lett. 1996, 386, 65-71.
38. van Tilbeurgh, H.; Egloff, M. P.; Martinez, C.; Rugani, N.; Verger, R. et al. Interfacial activation of the lipase-procolipase complex by mixed micelles revealed by X-ray crystallography. Nature 1993, 362, 814-820.
39. Lawson, D. M., Brzozowski, A. M., Dosson, G. G. Lifting the lid of lipases. Curr. Biol. 1992, 2, 473-475.
40. Velan, B.; Barak, D.; Ariel, N.; Leitner, M.; Bino, T. et al. Structural modifications of the omega loop in human acetylcholinesterase. FEBS Lett. 1996, 395, 22-28.
41. Millard, C. B.; Kryger, G.; Ordentlich, A.; Greenblatt, H. M.; Harel, M. et al. Crystal structures of aged phosphonylated acetylcholinesterase: nerve agent reaction products at the atomic level. Biochemistry 1999, 38, 7032-7039.
42. Carlacci, L.; Millard, C. B.; Olson, M. A. Conformational energy landscape of the acyl pocket loop in acetylcholinesterase: a Monte Carlo-generalized Born model study. Biophys. Chem. 2004, 111, 143-157.
43. Olson, M. A. Modeling loop reorganization free energies of acetylcholinesterase: a comparison of explicit and implicit solvent models. Proteins 2004, 57, 645-650.
44. Zeev-Ben-Mordehai, T.; Silman, I.; Sussman, J. L. Acetylcholinesterase in motion: visualizing conformational changes in crystal structures by a morphing procedure. Biopolymers 2003, 68, 395-406.
45. Bui, J. M.; Tai, K.; McCammon, J. A. Acetylcholinesterase: enhanced fluctuations and alternative routes to the active site in the complex with fasciculin-2. J. Am. Chem. Soc. 2004, 126, 7198-7205.
46. Kua, J.; Zhang, Y.; McCammon, J. A. Studying enzyme binding specificity in acetylcholinesterase using a combined molecular dynamics and multiple docking approach. J. Am. Chem. Soc. 2002, 124, 8260-8267.
47. Cavalli, A.; Bottegoni, G.; Raco, C.; De Vivo, M.; Recanatini, M. A computational study of the binding of propidium to the peripheral anionic site of human acetylcholinesterase. J. Med. Chem. 2004, 47, 3991-3999.
48. Barreiro, E. J.; Camara, C. A.; Verli, H.; Brazil-Mas, L.; Castro, N. G. et al. Design, synthesis, and pharmacological profile of novel fused pyrazolo[4,3-d]pyridine and pyrazolo[3,4-b][1,8] naphthyridine isosteres: a new class of potent and selective acetylcholinesterase inhibitors. J. Med. Chem. 2003, 46, 1144-1152.
49. Marco, J. L.; de los Rios, C.; Garcia, A. G.; Villarroya, M.; Carreiras, M. C. et al. Synthesis, biological evaluation and molecular modelling of diversely functionalized heterocyclic derivatives as inhibitors of acetylcholinesterase/butyrylcholinesterase and modulators of Ca2+ channels and nicotinic receptors. Bioorg. Med. Chem. 2004, 12, 2199-2218.
50. Barril, X., Gelpi, J. L., Lopez, J. M., Orozco, M., Luque, F. J. How accurate can molecular dynamics/linear response and Poisson-Boltzmann/ solvent accessible surface calculations be for predicting relative binding affinities? Acetylcholinesterase huprine inhibitors as a test ca. Theo. Chem. Acc. 2001, 106, 2-9.
51. Dvir, H.; Wong, D. M.; Harel, M.; Barril, X.; Orozco, M. et al. 3D structure of Torpedo californica acetylcholinesterase complexed with huprine X at 2.1 A resolution: kinetic and molecular dynamic correlates. Biochemistry 2002, 41, 2970-2981.
52. Bencsura, A., Enyedy, I., Kovach, I. M. Probing the Active Site of Acetylcholinesterase by Molecular Dynamics of its Phosphonate Ester Adducts. J. Am. Chem. Soc. 1996, 118, 8531-8541.
53. Enyedy, I. J.; Kovach, I. M.; Bencsura, A. Molecular dynamics study of active-site interactions with tetracoordinate transients in acetylcholinesterase and its mutants. Biochem. J. 2001, 353, 645-653.
54. Lane, R. M.; Kivipelto, M.; Greig, N. H. Acetylcholinesterase and its inhibition in Alzheimer disease. Clin. Neuropharmacol. 2004, 27, 141-149.
55. Pang, Y. P.; Kozikowski, A. P. Prediction of the binding site of 1-benzyl-4-[(5,6-dimethoxy-1-indanon-2-yl)methyl]piperidine in acetylcholinesterase by docking studies with the SYSDOC program. J. Comput. Aided Mol. Des. 1994, 8. 683-693.
56. Pang, Y. P., Kozikowski, A. P. Prediction of the binding sites of huperzine A in acetylcholinesterase by docking studies. J. Comput. Aided Mol. Des. 1994, 8, 669-681.
57. Eldridge, M. D. M., C. W.; Auton, R. R.; Paolini, G. V.; and Mee, R. P.; Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. J. Comp-Aided Mol. Design. 1997, 11, 425-445.
58. Gohlke, H. H., M.; Klebe, G.; Predicting Binding Modes, Binding Affinities and "Hot Spots" for Protein-Ligand Complexes Using a Knowledge-based Scoring Function. Persp. Drug Discov. Des. 2000, 20, 115-144.
59. Rarey M., K., B., Lengauer, T., and Klebe, G. A fast flexible docking method using an imcremental constructuion algorithm. J. Mol. Biol. 1996, 261, 470-489.
60. Jones, G. W., P.; Glen, R.; Leach, A. R. and Taylor, R.; Development and Validation of a Genetic Algorithm for Flexible Docking. J. Mol. Biol. 1997, 267, 727-748.
61. Muegge, I. a. M., Y. C.; A general and fast scoring function for protein-ligand interactions: a simplified potential approach. J. Med. Chem. 1999, 42, 791-804.
62. Guo, J., Hurley, M. M., Wright, J. B., Lushington, G. H. A docking score function for estimating ligand-protein interactions: application to acetylcholinesterase inhibition. J. Med. Chem. 2004, 47, 5492-5500.
63. Totrov, M.; Abagyan, R. Flexible protein-ligand docking by global energy optimization in internal coordinates. Proteins 1997, Suppl 1, 215-220.
64. Kryger, G.; Silman, I.; Sussman, J. L. Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs. Structure Fold Des. 1999, 7, 297-307.
65. Morris, G. M., Goodsell, D. S., Halliday, R. S., Huey, R., Hart, W. E., Belew, R. K., Olson, A. J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 1998, 19, 1639-1662.
66. Cho, S. J., Garsia, M. L., Bier, J., Tropsha, A. Structure-based alignment and comparative molecular field analysis of acetylcholinesterase inhibitors. J. Med. Chem. 1996, 39, 5064-5071.
67. Bernard, P., Kireev, D. B., Chretien, J. R., Fortier, P. L., Coppet, L. Automated docking of 82 N-benzylpiperidine derivatives to mouse acetylcholinesterase and comparative molecular field analysis with 'natural' alignment. J. Comput. Aided Mol. Des. 1999, 13, 355-371.
68. Sippl, W., Contreras, J. M., Parrot, I., Rival, Y. M., Wermuth, C. G. Structure-based 3D QSAR and design of novel acetylcholinesterase inhibitors. J. Comput. Aided Mol. Des. 2001, 15, 395-410.
69. Goodford, P. J. GRID; Molecular Discovery Ltd,: University of Oxford, England.
70. Clementi, S. GOLPE; Multivariate Informetric Analyses(MIA),: Perugia, Italy.
71. Wade, R. C. Derivation of QSARs using 3D structural models of protein-ligand complexes by COMBINE analysis. Rational Approaches to Drug Design, Proceedings of the European Symposium on Quantitative Structure-Activity Relationships,: Duesseldorf, Germany, 2000; pp 23-28.
72. Martin-Santamaria, S., Munoz-Muriedas, J., Luque, F. J., Gago, F. Modulation of binding strength in several classes of active site inhibitors of acetylcholinesterase studied by comparative binding energy analysis. J. Med. Chem. 2004, 47, 4471-4482.
73. Mizutani, M. Y.; Itai, A. Efficient method for high-throughput virtual screening based on flexible docking: discovery of novel acetylcholinesterase inhibitors. J. Med. Chem. 2004, 47, 4818-4828.
74. Camps, P.; Formosa, X.; Munoz-Torrero, D.; Petrignet, J.; Badia, A. et al. Synthesis and pharmacological evaluation of huprinetacrine heterodimers: subnanomolar dual binding site acetylcholinesterase inhibitors. J. Med. Chem. 2005, 48, 1701-1704.
75. Vasilyev, V. V. Tetrahedral intermediate formation in the acylation step of acetylcholinesterases. A combined quantum chemical and molecular mechanical model. J. Mol. Struc. (Theochem) 1994, 304, 129-141.
76. Wlodek, S. T., Antosiewicz, J., Briggs, J. M. On the mechanism of acetylcholinesterase action: the electrostatically induced acceleration of the catalytic acylation step. J. Am. Chem. Soc. 1997, 119, 8159-8165.
77. Fuxreiter, M., Warshel, A. Origin of the catalytic power of aetylcholinesterase: computer simulation studies. J. Am. Chem. Soc. 1998, 120, 183-194.
78. Vagedes, P., Rabenstein, B., Agvist, J., Marelius, J., Knapp, W.-W. The deacylation step of acetylcholinesterase: computer simulation studies. J. Am. Chem. Soc. 2000, 122, 12254-12262.
79. Zhang, Y.; Kua, J.; McCammon, J. A. Role of the catalytic triad and oxyanion hole in acetylcholinesterase catalysis: an ab initio QM/MM study. J. Am. Chem. Soc. 2002, 124, 10572-10577.
80. Ekholm, M. Predicting relative binding free energies of subtstrates and inhibitors of acetylcholin- and butyrylcholinesterases. J. Mol. Struc. (Theochem) 2001, 572, 25-34.
81. Bencsura, A.; Enyedy, I.; Kovach, I. M. Origins and diversity of the aging reaction in phosphonate adducts of serine hydrolase enzymes: what characteristics of the active site do they probe? Biochemistry 1995, 34, 8989-8999.
82. Albaret, C.; Lacoutiere, S.; Ashman, W. P.; Froment, D.; Fortier, P. L. Molecular mechanic study of nerve agent O-ethyl S-[2-(diisopropylamino) ethyl]methylphosphonothioate (VX) bound to the active site of Torpedo californica acetylcholinesterase. Proteins 1997, 28, 543-555.
83. Hurley, M. M., Wright, J. B., Lushington, G. H., White, W. E. Quantum mechanics and mixed quantum mechanics/molecular mechanics simulations of model nerve agents with acetylcholinesterase. Theo. Chem. Acc. 2003, 109, 160-168.
84. Wright, J. B., Lushington, G. H., Hurley, M. M. Role of solvent in organophosphorus binding to acetylcholinestase. In preparation.
85. Millard, C. B., Koellner, G., Ordentlich, A., Shafferman, A., Silman, I., Sussman, J. L. Reaction Products of Acetylcholinesterase and VX Reveal a Mobile Histidine in the Catalytic Triad. J. Am. Chem. Soc. 1999, 121, 9883-9884.
86. Massiah, M. A.; Viragh, C.; Reddy, P. M.; Kovach, I. M.; Johnson, J. et al. Short, strong hydrogen bonds at the active site of human acetylcholinesterase: proton NMR studies. Biochemistry 2001, 40, 5682-5690.
87. Hurley, M. B., A.; Wright, J.; Lushington G. Defense Against Chemical Warfare Agents (CWAs) and Toxic Industrial Chemicals (TICs). Proceedings of the 2004 DoD High Performance Computing Modernization Program Users Group Conference: Williamsburg, Virgina, 2004; pp 20-26.
88. Hurley, M. M., Balboa, A., Lushington, G. H., Guo, J. Interactions of Organophosphorus and Related Compounds with Cholinesterases, a Theoretical Study. Chem. Biol. Interact. in press.
89. Su, C. T.; Lien, E. J. QSAR of acetylchol inesterase inhibitors: a reexamination of the role of charge-transfer. Res. Commun. Chem. Pathol. Pharmacol. 1980, 29, 403-415.
90. Cardozo, M. G., Iimura, Y., Sugimoto, H., Yamanishi, Y., Hopfinger, A. J. QSAR analyses of the substituted indanone and benzylpiperidine rings of a series of indanone-benzylpiperidine inhibitors of acetylcholinesterase. J. Med. Chem. 1992, 35, 584-589.
91. Tong, W., Collantes, E. R., Chen, Y., Welsh, W. J. A comparative molecular field analysis study of N-benzylpiperidines as acetylcholinesterase inhibitors. J. Med. Chem. 1996, 39, 380-387.
92. Hasegawa, K.; Kimura, T.; Funatsu, K. GA strategy for variable selection in QSAR studies: application of GA-based region selection to a 3D-QSAR study of acetylcholinesterase inhibitors. J. Chem. Inf. Comput. Sci. 1999, 39, 112-120.
93. Sulea, T., Kurunczi, L., Oprea, T. I., Simon, Z. MTD-ADJ: a multiconformational minimal topologic difference for determining bioactive conformers using adjusted biological activities. J. Comput. Aided Mol. Des. 1998, 12, 133-146.
94. Dewar, M. J. S., Zoebisch, E. G., Healy, E. F., Stewart, J. J. P. AM1: A new general purpose quantum mechanical model. J. Am. Chem. Soc. 1995, 107, 3902-3909.
95. Eldred, D. V., Jurs, P. C. Prediction of acute mammalian toxicity of organophosphorus pesticide compounds from molecular structure. SAR and QSAR in envir. Res. 1999, 10, 75-99.
96. El Yazal, J.; Rao, S. N.; Mehl, A.; Slikker, W., Jr. Prediction of organophosphorus acetylcholinesterase inhibition using three-dimensional quantitative structure-activity relationship (3D-QSAR) methods. Toxicol. Sci. 2001, 63, 223-232.
97. Zhao, J., Wang, B., Dai, Z., Wang, X., Kong, L., Wang, L. 3D-quantitative structure-activity relationship study of organophosphate compounds. Chinese Science bulletin 2004, 49, 240-245.
98. Bernard, P. P., Kireev, D. B., Pintore, M., Chretien, J. R., Fortier, P.-L. Froment, D. A CoMFA study of enantiomeric organophosphorus inhibitors of acetylcholinesterase. J. Mol. Model. 2000, 6, 618-629.
99. Cashman, J. R.; Perotti, B. Y.; Berkman, C. E.; Lin, J. Pharmacokinetics and molecular detoxication. Environ Health Perspect 1996, 104 Suppl 1, 23-40.
100. Guo, J.-X., Wu,J.J.-Q., Wright, J.B., Lushington, G.H. Mechanistic Insight into Acetylcholinesterase Inhibition and Acute Toxicity of Organophosphorus Compounds: a Molecular Modeling Study. Chem. Res. Toxicol. in press.
101. Tai, K. S. Simulations on many scales: The synapse as an example. Pure Applied Chem. 2004, 76, 295-302.
102. Hamelberg, D., Dongan, J., McCammon, J. A. Accelerated molecular dynamics: a promising and efficient simulation method for biomolecules. J. Chem. Phys. 2004, 120, 11919-11929.
103. Chen, X.-W. An Improved Branch and Bound Algorithm for Feature Selection. Pattern Recog. Lett. 2003, 24, 1925-1933.
104. Hamelberg, D.; Shen, T.; McCammon, J. A. Phosphorylation effects on cis/ trans isomerization and the backbone conformation of serine-proline motifs: accelerated molecular dynamics analysis. J. Am. Chem. Soc. 2005, 127, 1969-1974.
105. Song, Y.; Zhang, Y.; Shen, T.; Bajaj, C. L.; McCammon, J. A. et al. Finite element solution of the steady-state Smoluchowski equation for rate constant calculations. Biophys. J. 2004, 86, 2017-2029.
106. Zhang, D.; Suen, J.; Zhang, Y.; Song, Y.; Radic, Z. et al. Tetrameric mouse acetylcholinesterase: continuum diffusion rate calculations by solving the steady-state Smoluchowski equation using finite element methods. Biophys J 2005, 88, 1659-1665.
107. Colombo, M. C., Guidoni, L., laio, A., Magistrato, A., Maurer, P., Piana, S., rohrig, U., Spiegel, K., Sulpizi, M., VandeVondele, J., Zumstein, M., rothlisberger, U. Hybrid QM/MM Car-Parrinello simulations of catalytic and enzymatic reactions. Chimia 2002, 56, 13-19.